Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China 9h
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy 04 February
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options 28 January
